Brief: Exelixis announces detailed results from late-stage pivotal trial
20/10/2025 10:52
Oct 20 (Reuters) - Exelixis Inc EXEL.O: EXELIXIS ANNOUNCES DETAILED RESULTS FROM PHASE 3 STELLAR-303 PIVOTAL TRIAL EVALUATING ZANZALINTINIB IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR IN METASTATIC COLORECTAL CANCER PRESENTED AT ESMO 2025 AND PUBLISHED IN THE LANCET EXELIXIS INC - ZANZALINTINIB WITH ATEZOLIZUMAB IMPROVES MEDIAN OVERALL SURVIVAL TO 10.9 MONTHS EXELIXIS INC - PLANS NEW DRUG APPLICATION FOR ZANZALINTINIB IN US IN 2025 Source text: ID:nBw8CPxyPa Further company coverage: EXEL.O ((Reuters.Briefs@thomsonreuters.com;))